| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Patients across the U.S. will soon have access to a new cervical cancer test collected from the comfort of their own home—no stirrups, speculum, or in-person doctor’s visit needed. The life sciences company Waters is partnering with Quest Diagnostics to make Waters’ Onclarity HPV Self-Collection Kit available for use at home. The partnership, announced Tuesday, will begin making self-collection kits available in early 2027.
We’re taking a closer look at new research highlighting the risks of tick-borne diseases. A study by Quest Diagnostics, published in JAMA Network Open, found that nearly one in three patients with antibodies for Lyme disease also had antibodies for at least one other tick-borne pathogen. Joining us to break down the findings and explain what they mean for diagnosis and treatment is Dr. Emily Schindler, Medical Director of Infectious Disease and Immunology at Quest Diagnostics.
Quest Diagnostics calls for passage of RESULTS Act as survey shows 96% of voters value lab testing. Claire Wallace,Senior Writer,Informa Markets – Engineering Quest Diagnostics is calling on Congress to pass the RESULTS Act before scheduled Medicare laboratory payment cuts take effect in January 2027, citing new survey data showing overwhelming public support for protecting access to diagnostic testing and concerns about the flawed rate-setting process under current law.
The ctDNA liquid biopsy demonstrated 100% specificity and outperformed standard CEA testing in residual specimen analysis. A study published in The Journal of Molecular Diagnostics shows that the Haystack MRD test accurately detects residual and recurrent colorectal cancer, demonstrating clinical performance in patient specimens from the DYNAMIC clinical trial series. The study also validated the test’s analytical performance across 23 solid tumor types.
Despite the surge of people who embraced healthier lifestyles amid the new perspectives they’d gained during the pandemic, drug use still remains significant among U.S. workers. Recent data analysis by testing company Quest Diagnostics found that nearly 20 percent of employees generated positive results for a range of illicit substances in 2025, “potentially reflecting recurring or chronic drug use.”